相关实验视频

Updated: Sep 15, 2025

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors

Published on: May 9, 2025

准PARP14:通过3D-QSAR药模拟和分子动态识别新型竞争性抑制剂的in silico框架

Manisha Agarwal¹, Sanchaita Rajkhowa¹, Magdi E A Zaki²

¹Centre for Biotechnology and Bioinformatics, Dibrugarh University, Dibrugarh, Assam, 786004, India.

Computers in biology and medicine

|July 17, 2025

概括

这项研究将现有药物重新定位为癌症治疗的新型PARP14抑制剂. 罗塞米德和维拉佐显示出对重定向的承诺,而STOCK1N-42868则是进一步研究的新候选人.

科学领域:

生物化学和分子生物学
计算化学计算化学
药理学药理学是一个学科.

背景情况:

翻译后的修改,包括由多基基聚合酶 (PARP) 酶催化ADP-ribosylation,调节关键的细胞过程.
PARP14是一种单-ADP-ribosyltransferase,与癌症的发展和进展有关,使其成为潜在的治疗点.
过度表达PARP14与侵袭性B细胞淋巴瘤和转移性前列腺癌有关.

研究的目的:

通过重新利用现有的化合物来识别用于抗癌应用的新型PARP14抑制剂.
为药物发现利用基于联体的计算策略.
探索Furosemide和Vilazodone作为PARP14抑制剂的潜力,并确定新的候选药物.

主要方法:

使用3D定量结构-活性关系和用60种已知的PARP14抑制剂制造药模型的药模型 (Hypo1) 的开发.
从DrugBank和IBScreen图书馆中虚拟选超过71540种化合物.
分子对接,药物类似性质的评估 (维伯和利宾斯基规则),ADMET分析,分子动力学模拟和MM-PBSA分析.

主要成果:

为了准确的虚拟查,建立了一个可靠的药模型 (Hypo1).
他们发现了四种有前途的候选药物:富洛塞米德,维拉佐,STOCK1N-42868和STOCK1N-92908.8.
富罗塞米德和维拉佐显示出显著的结合亲和力和抗癌潜力,这表明有效的重定位. STOCK1N-42868成为了一种新型候选物,具有有前途的in silico结果.

结论:

罗塞米德和维拉佐有可能被重新定位为PARP14抑制剂,以提高癌症治疗效率.
STOCK1N-42868代表了一种新的化合物,作为PARP14抑制剂进行进一步研究.
计算方法对于识别新药候选药物非常有价值,强调了临床前验证的必要性.

关键词:

在3D-QSAR建模中使用3D-QSAR模型.癌症药物发现的发现药物重新定位是药物重新定位.二化物是一种二化物.一个单-ADP-Ribosyl转移酶.这是一种PARP14抑制剂.维拉佐龙是一种维拉佐.

更多相关视频

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors

Published on: October 26, 2015

Biosensor-based High Throughput Biopanning and Bioinformatics Analysis Strategy for the Global Validation of Drug-protein Interactions

Biosensor-based High Throughput Biopanning and Bioinformatics Analysis Strategy for the Global Validation of Drug-protein Interactions

Published on: December 1, 2020

相关概念视频

Structure-Activity Relationships and Drug Design

Structure-Activity Relationships and Drug Design

Drug design is a dynamic field that involves discovering and developing new medications based on specific biological targets. This process heavily relies on structure-activity relationships (SAR) and quantitative structure-activity relationships (QSAR) to guide the design and optimization of efficient drugs.
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...

Protein-protein Interfaces

Protein-protein Interfaces

Many proteins form complexes to carry out their functions, making protein-protein interactions (PPIs) essential for an organism's survival. Most PPIs are stabilized by numerous weak noncovalent chemical forces. The physical shape of the interfaces determines the way two proteins interact. Many globular proteins have closely-matching shapes on their surfaces, which form a large number of weak bonds. Additionally, many PPIs occur between two helices or between a surface cleft and a...